Voyager Therapeutics (VYGR)

• Market cap: $232M
• 1 day: -4.57%
• 5 days: -4.13%
• 1 month: 23.3%
• 3 months: 16.11%
• 6 months: 2.96%
• Year to date: -29.98%
• 1 year: -32.8%
• 5 years: -59.81%
• 10 years: -76.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 172

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

62% more call options, than puts

Call options by funds: $120K | Put options by funds: $74K

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

2.88% less ownership

Funds ownership: 62.84% [Q1] → 59.96% (-2.88%) [Q2]

4% less funds holding

Funds holding: 115 [Q1] → 110 (-5) [Q2]

12% less capital invested

Capital invested by funds: $117M [Q1] → $103M (-$14.2M) [Q2]

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8
• Avg. target: $8
• High target: $8

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Wedbush Yun Zhong

$8

Outperform Maintained

7 Aug 2025